Literature DB >> 14581403

Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS).

Ken Williams1, Allan D Sniderman, Naveed Sattar, Ralph D'Agostino, Lynne E Wagenknecht, Steven M Haffner.   

Abstract

BACKGROUND: Risk factors for vascular disease include obesity, dyslipidemia, hypertension, dysglycemia, insulin resistance, inflammation, thrombosis, and subclinical atherosclerosis. This study compares the associations of apolipoprotein B (apoB) and LDL cholesterol (LDLC) with a wide array of measures of these risk factors. METHODS AND
RESULTS: In 1522 individuals in the Insulin Resistance Atherosclerosis Study, anthropometric measures and measures of lipids, apoB, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1 (PAI-1), fasting and postglucose load glucose and insulin concentrations, and carotid artery intima-media thickness (IMT) were taken and insulin sensitivity was determined by frequently sampled intravenous glucose tolerance test. There were significant differences in measures of abdominal obesity, dyslipidemia, hyperinsulinemia, and thrombosis between subjects with elevated apoB but normal LDLC versus those with elevated LDLC but normal apoB. In each statistically significant comparison, the elevated-apoB group had higher associated risk than the elevated-LDLC group. Moreover, apoB is highly significantly (P<0.0001) correlated with each measure in the direction of higher risk, whereas LDLC was significantly correlated (P<0.05) only with blood pressure, triglyceride, fibrinogen, and C-reactive protein. After further adjustment for LDLC, apoB correlations remained significant, whereas several LDLC correlations adjusted for apoB became significant in the direction of lower risk.
CONCLUSIONS: Elevated apoB is more strongly associated than LDLC with other risk factors, including measures in the National Cholesterol Education Program guidelines for lipid treatment and other more recently established risk factors. This may provide new insight into why apoB is a better predictor of vascular risk than LDLC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581403     DOI: 10.1161/01.CIR.0000097113.11419.9E

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial.

Authors:  Jeremy D Furtado; Hannia Campos; Anne E Sumner; Lawrence J Appel; Vincent J Carey; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2010-09-08       Impact factor: 7.045

Review 2.  Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics.

Authors:  Julio D Duarte; Rhonda M Cooper-DeHoff
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-06

3.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

4.  Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

Authors:  Jean-Claude Ansquer; Christophe Corda; Karine Le Malicot; Valerie Jessent
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

5.  Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women.

Authors:  M Faraj; L Messier; J P Bastard; A Tardif; A Godbout; D Prud'homme; R Rabasa-Lhoret
Journal:  Diabetologia       Date:  2006-05-03       Impact factor: 10.122

Review 6.  Clinical significance of the physicochemical properties of LDL in type 2 diabetes.

Authors:  P G Scheffer; T Teerlink; R J Heine
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

7.  Molecular correlates of spontaneous activity in non-human primates.

Authors:  Amanda C Mitchell; Georgina Aldridge; Shawn Kohler; Greg Stanton; Elinor Sullivan; Krassimira Garbett; Gabor Faludi; Károly Mirnics; Judy L Cameron; William Greenough
Journal:  J Neural Transm (Vienna)       Date:  2010-09-14       Impact factor: 3.575

8.  Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial.

Authors:  Jeremy D Furtado; Hannia Campos; Lawrence J Appel; Edgar R Miller; Nancy Laranjo; Vincent J Carey; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2008-06       Impact factor: 7.045

9.  The effects of exercise on lipid profile in systemic lupus erythematosus and healthy individuals: a randomized trial.

Authors:  Fabiana Braga Benatti; Renata Miossi; Marisa Passareli; Edna R Nakandakare; Luiz Perandini; Fernanda Rodrigues Lima; Hamilton Roschel; Eduardo Borba; Eloisa Bonfá; Bruno Gualano; Ana Lúcia de Sá Pinto
Journal:  Rheumatol Int       Date:  2014-06-28       Impact factor: 2.631

Review 10.  Apolipoprotein measurements: is more widespread use clinically indicated?

Authors:  Michael H Davidson
Journal:  Clin Cardiol       Date:  2009-09       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.